Diagnosis of α0-thalassemia Chiang Rai (--CR) deletion by melt curve analysis in Northern Thailand

A large novel 44.6 kb deletion named α⁰-thalassemia Chiang Rai (--^CR) was first described in the individuals with uncommon Hb Bart's hydrops fetalis and HbH disease. This study aimed to develop a real-time gap PCR and melt curve analysis for the detection of --^CR and investigate its frequency in northern Thailand. Among 4,952 blood samples, the assay was performed in 525 samples with a mean corpuscular volume (MCV) < 80 fL, HbA₂ < 3.5%, HbA₂+E < 25%, and negative for common deletional α⁰-thalassemia --^SEA and --^THAI. The developed method showed T_m values of 85.8 ± 0.0 °C and 91.5 ± 0.1 °C, which were specific for --^CR and wild-type alleles, respectively. Nine (0.18% of 4,952 or 1.71% of 525) were positive for --^CR, in which two were HbH disease and the rest were heterozygous for --^CR. This study demonstrated the success of real-time gap PCR with melt curve analysis for --^CR diagnosis. Additionally, the prevalence of --^CR in the northern Thai population was comparable to --^THAI. Thus, this study implies the importance of --^CR in northern Thailand. Moreover, the developed real-time gap PCR with melt curve analysis is simple and highly accurate, and may be considered as an additional tool for routine α⁰-thalassemia --^CR diagnosis in this region.

Whole Blood PCR for Rapid Screening of α0-Thalassemia

Hemoglobin Bart's hydrops fetalis (homozygous α⁰-thalassemia) is the most severe form of thalassemia in the Southeast Asian population. Fetuses with this disorder almost always die in utero or shortly after birth. Screening of α⁰-thalassemia carrier is therefore crucial. Currently, diagnosis of α⁰-thalassemia genes is done by DNA-based analysis which relies on DNA extraction. We have developed a simple screening format based on whole blood PCR assay. The method was validated on 198 specimens and the results show 100% concordance with a conventional gap-PCR on DNA specimens. The protocol could also be applied to amniotic fluid specimens in prenatal diagnostic testing. The assay developed should facilitate carrier screening and prenatal diagnosis of Hb Bart's hydrops fetalis syndrome in the region.

Novel interactions of two α-Hb variants with SEA deletion α0-thalassemia: hematological and molecular analyses

OBJECTIVES

To report the hematological and molecular features as well as diagnostic aspects of the hitherto un-described interactions of two rare α-globin chain variants with α⁰-thalassemia commonly found among Southeast Asian populations.

METHODS

The study was done on two adult Thai patients (P1 and P2) who had hypochromic microcytic anemia. Hb analysis was carried out using high performance liquid chromatography (HPLC) and capillary electrophoresis (CE). Mutations were identified by PCR and related techniques.

RESULTS

Hb analysis of P1 using HPLC showed a normal Hb pattern, but CE demonstrated an abnormal peak at zone 7. DNA sequencing identified a CCG-CTG mutation at codon 95 of the α2 globin gene corresponding to the Hb G-Georgia [α95(G2)Pro → Leu(α2)] previously undescribed in the Thai population. In contrast, Hb analysis of P2 demonstrated an abnormal peak not fully separated from Hb A on HPLC, but not on CE. DNA analysis identified the rarely described Hb Nakhon Ratchasima [α63(E12)Ala → Val(α2)] mutation. Routine DNA analysis detected the SEA deletion α⁰-thalassemia in trans to the Hb variants in both cases. Hematological parameters were compared with those of patients with compound heterozygote for other α-globin variants and α⁰-thalassemia previously documented.

CONCLUSIONS

Identification of the patients confirmed that interaction of these rare Hb variants with α⁰-thalassemia does not lead to the Hb H disease. Differentiation of these two Hb variants from other clinically relevant hemoglobinopathies in a routine setting is, however, necessary. This can be accomplished using a combined Hb-HPLC and CE analysis followed by PCR-RFLP assays.

Co-inheritance of α0 -thalassemia elevates Hb A2 level in homozygous Hb E: Diagnostic implications

INTRODUCTION

Differentiation of homozygous hemoglobin (Hb) E with and without α⁰ -thalassemia is subtle on routine hematological ground. We examined in a large cohort of homozygous Hb E if the level of Hb A₂ is helpful.

METHODS

A total of 592 subjects with homozygous Hb E were recruited from ongoing thalassemia screening program. Additionally, five couples at risk of having fetuses with Hb Bart's hydrops fetalis who were homozygous Hb E were also investigated. Hb analysis was performed using capillary electrophoresis system. Globin genotypes were defined by DNA analysis.

RESULTS

Subjects were classified into four groups including pure homozygous Hb E (n=532), homozygous Hb E/α⁰ -thalassemia (n=48), Hb Constant Spring EE Bart's disease (n=8), and Hb EE Bart's disease (n=4). The levels of Hb A₂ were found, respectively, to be 4.97±0.69, 6.64±1.02, 4.86±0.87, and 7.60±1.04%. Among five couples at risk, α⁰ -thalassemia was identified in three subjects with Hb A₂ >6.0%.

CONCLUSIONS

Increased Hb A₂ level is a useful marker for differentiation of homozygous Hb E with and without α⁰ -thalassemia. This should lead to a significant reduction in number of referral cases of homozygous Hb E for molecular testing of α⁰ -thalassemia in routine practice.

First-trimester combined screening for trisomy 21 in women at risk for α-thalassemia

OBJECTIVE

To report the strategy of first-trimester aneuploidy screening in pregnancies at risk for homozygous α(0)-thalassemian.

METHODS

Women at risk of homozygous α(0)-thalassemia were given an ultrasound examination at 11-14 weeks' gestation to exclude an affected pregnancy. Fetal cardiothoracic ratio (CTR) and nuchal translucence (NT) were measured. If cardiomegaly was found, chorionic villus sampling (CVS) was offered for α-thalassemia; otherwise the first-trimester combined screening test was performed on the pregnancy. The invasive testing for karyotyping was only followed in those cases with a positive aneuploidy screening test.

RESULTS

In total, 69 of 288 pregnancies were found to be affected by homozygous α(0)-thalassemia using ultrasound, and the findings were confirmed by invasive testing. In the remaining 219 pregnancies, invasive testing was not performed for α-thalassemia because of a normal fetal CTR, and the women received the first-trimester combined screening. Nine CVS procedures were performed for karyotyping because of a positive aneuploidy screening. Totally three pregnancies with aneuploidy were diagnosed and terminated.

CONCLUSIONS

Our strategy can selectively detect aneuploidy pregnancies not affected by homozygous α-thalassemia, and, meanwhile, save on the cost of unnecessary aneuploidy screening or karyotyping in pregnancies with an affected fetus of homozygous α(0)-thalassemia.